Back

Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapies: new findings Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Iryna Dykun

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

8 More presentations in this session

Presentation thumbnail
Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia
Doctor D. Gaudet (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Changes in lipid lowering therapy one year after percutaneous coronary intervention: data from the large contemporary ZON-HR registry
Ms D. Peeters (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
Doctor D. Mutschlechner (Mistelbach, AT)
Abstract Slides Video
Presentation thumbnail
Association of lipid target achievement and cardiovascular outcomes following statin initiation: a population-based cohort study
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
Doctor H. Tsubata (Kyoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapies: new findings

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
thumbnail
Congress Presentation
Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study
thumbnail
Congress Presentation
Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources